Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation
Autor: | Salih Emri, Mert C. Ongun, Elif Tugce Korkmaz, Erdem Karabulut, Alper B. Iskit, Melih O. Babaoglu, Elif Babaoglu, Ahmet Muderrisoglu |
---|---|
Přispěvatelé: | KKÜ |
Rok vydání: | 2020 |
Předmět: |
cytochrome P450 enzymes
medicine.medical_specialty CYP2B6 lcsh:QH426-470 medicine.medical_treatment media_common.quotation_subject P-glycoprotein Nicotine chemistry.chemical_compound Internal medicine medicine Genetics genetic polymorphism Varenicline CYP2A6 Genetics (clinical) media_common Original Research Bupropion business.industry Addiction Nicotine replacement therapy lcsh:Genetics chemistry behavior and behavior mechanisms Molecular Medicine Smoking cessation addiction business medicine.drug nicotine |
Zdroj: | Frontiers in Genetics Frontiers in Genetics, Vol 11 (2020) |
ISSN: | 1664-8021 |
Popis: | ObjectivesTo determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.Methods130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (n = 40), bupropion (n = 47), bupropion + NRT (n = 15), and varenicline (n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.ResultsCessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (p = 0.652, p = 0.328, respectively), or variants of CYP2B6 (p = 0.514, p = 0.779, respectively).ConclusionGenetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |